Literature DB >> 18638220

Autoantibodies to basement membrane proteins BP180 and BP230 are commonly detected in normal subjects by immunoblotting.

Nemesha Desai1, Jill Allen, Iaisha Ali, Vanessa Venning, Fenella Wojnarowska.   

Abstract

Autoantibodies to basement membrane proteins BP180 and BP230 are characteristic of bullous pemphigoid and other subepidermal immunobullous disorders. These antibodies are, however, reported in other pruritic dermatoses, non-bullous disorders and non-cutaneous disease. Few studies have assessed basement membrane antibodies in normal subjects; antibody prevalence in this population is not clear. This study aims to examine basement membrane zone antibodies in normal middle-aged to elderly subjects. Sera from 61 healthy subjects (majority age 50-70 years) were assessed by immunoblot, indirect immunofluorescence and enzyme-linked immunosorbent assay. Ninety-one bullous pemphigoid patients acted as positive controls. Antigenic target, antibody class and titre were examined; sera binding BP180 were assessed for reactivity to the non-collagenous 16A (NC16A) domain. Thirty-six normal subjects (59%) had antibodies to either BP180 or BP230 on immunoblot analysis. BP180 was the commonest target antigen, detected in 35 subjects; binding to the immunodominant NC16A domain was not detected. Immunofluorescence was positive in three subjects. Of the bullous pemphigoid sera, 88% were positive on immunoblot or immunofluorescence; a higher frequency had antibodies against BP230. In conclusion, significant numbers of normal healthy subjects have circulating autoantibodies to basement membrane proteins, chiefly BP180 detectable by immunoblot, but these do not bind the NC16A domain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638220     DOI: 10.1111/j.1440-0960.2008.00452.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  5 in total

Review 1.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

2.  Prevalence of pemphigus and pemphigoid autoantibodies in the general population.

Authors:  Wiebke Prüßmann; Jasper Prüßmann; Hiroshi Koga; Andreas Recke; Hiroaki Iwata; David Juhl; Siegfried Görg; Reinhard Henschler; Takashi Hashimoto; Enno Schmidt; Detlef Zillikens; Saleh M Ibrahim; Ralf J Ludwig
Journal:  Orphanet J Rare Dis       Date:  2015-05-15       Impact factor: 4.123

Review 3.  Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid.

Authors:  Connor Cole; Luca Borradori; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2022-06-28

4.  Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.

Authors:  Antti Nätynki; Päivi Leisti; Jussi Tuusa; Outi Varpuluoma; Laura Huilaja; Kentaro Izumi; Sanna-Kaisa Herukka; Olavi Ukkola; Juhani Junttila; Nina Kokkonen; Kaisa Tasanen
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 5.  The significance of preclinical anti-BP180 autoantibodies.

Authors:  Yosuke Mai; Kentaro Izumi; Shoko Mai; Hideyuki Ujiie
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.